Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.1.7 (acetylcholinesterase)
28,390 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Paraoxon, an irreversible organophosphorus inhibitor of cholinesterase, produces a myopathy beginning at the neuromuscular junction in rat diaphragm muscles. Thirty minutes after paraoxon was injected i.p. (0.5 mg/kg), neuromuscular cholinesterase activity was reduced to 36% of control. The frequency of miniature end-plate potentials (MEPPs) in diaphragms from paraoxon-treated rats was 109/sec compared with 2.9/sec in saline-injected controls. The faster frequency was seen after paraoxon gradually declined to control rates within 6 hours after injection. The quantum content of end-plate potentials was reduced to 66% of that seen in saline controls. Spontaneous and impulse-related antidromic activity was observed along the phrenic nerve after paraoxon which also gradually diminished with time. When the phosphorylated acetylcholinesterase was reactivated with 10(-3) pyridine-2-aldoxime methiodide, MEPP frequency was reduced significantly and antidromic activity was abolished. Block of axonal excitability with 10(-6) M tetrodotoxin reduces the effects of paraoxon on MEPP frequency and antidromic activity, while acetylcholinesterase remains inhibited. In vitro perfusion with 6 times 10(-8) M paraoxon increases MEPP frequency and initiates antidromic activity. It is concluded that inhibition of neuromuscular cholinesterase by paraoxon leads to an alteration of transmitter release, and this may be associated with ultrastructural abnormalities observed at the motor endplate.
...
PMID:Presynaptic effects of neuromuscular cholinesterase inhibition. 115 64

In the presence of paraoxon, the amplitudes of chloride currents activated by acetylcholine (ACh) or gamma-aminobutyric acid (GABA) were reduced in cell R2 of Aplysia californica. IC50 values were 12 and 9.7 microM for ACh and GABA responses, respectively. Paraoxon did not affect resting membrane potential, input resistance, or chloride reversal potential. Both the slopes and maxima of ACh and GABA concentration-response curves were reduced by paraoxon, suggesting that paraoxon antagonism of these responses is not competitive. The antagonism of ACh and GABA responses by paraoxon was not related to inhibition of acetylcholinesterase.
...
PMID:Paraoxon block of chloride conductance in cell R2 of Aplysia californica. 137 24

The binding of [3H] quinuclidinyl benzilate (QNB) to rat striatum membranes after diisopropylfluorophosphate (DFP) induced seizures was characterized. There was a 36% decrease in Kd and a 33% decrease in the number of muscarinic receptors. Paraoxon caused inhibition fo [3H] QNB binding to the striatal membranes of intact rats. It is possible that a direct action of DFP on the muscarinic receptor is not the cause of anti-cholinesterase-induced changes in [3H] QNB binding.
...
PMID:[Effects of diisopropylfluorophosphate, paraoxon and dichlophos on [3H] quinuclidinyl benzylate binding to the rat striatum synaptic membranes]. 147 63

Cholinesterases of porcine left ventricular heart muscle were characterized with respect to substrate specificity and inhibition kinetics with organophosphorus inhibitors N,N'-di-isopropyl-phosphorodiamidic fluoride (Mipafox), di-isopropylphosphorofluoridate (DFP), and diethyl p-nitro-phenyl phosphate (Paraoxon). Total myocardial choline ester hydrolysing activity (234 nmol/min/g wet wt with 1.5 mM acetylthiocholine, ASCh; 216 nmol/min/g with 30 mM butyrylthiocholine, BSCh) was irreversibly and covalently inhibited by a wide range of inhibitor concentrations and, using weighted least-squares non-linear curve fitting, residual activities as determined with four different substrates in each case were fitted to a sum of up to four exponential functions. Quality of curve fitting as assessed by the sum of squares reached its optimum on the basis of a three component model, thus, indicating the presence of three different enzymes taking part in choline ester hydrolysis. Final classification of heart muscle cholinesterases was obtained according to both substrate hydrolysis patterns with ASCh, BSCh, acetyl-beta-methylthiocholine and propionylthiocholine, and second-order rate constants for the reaction with organophosphorus inhibitors Mipafox, DFP, and Paraoxon. One choline ester-hydrolysing enzyme was identified as acetylcholinesterase (EC 3.1.1.7), and one as butyrylcholinesterase (EC 3.1.1.8). The third enzyme with relative resistance to organophosphorus inhibition was classified as atypical cholinesterase.
...
PMID:Cholinesterases of heart muscle. Characterization of multiple enzymes using kinetics of irreversible organophosphorus inhibition. 154 Feb 36

Paraoxon and chlorpyrifos-oxon, the active metabolites of the organophosphorus insecticides parathion and chlorpyrifos, respectively, are hydrolyzed by an "A"-esterase, paraoxonase, which is present in the sera of several mammalian species. In this study, we investigated whether levels of serum paraoxonase activity in laboratory animals can influence the in vivo toxicity of paraoxon and chlorpyrifos-oxon. Paraoxonase was found to be 7-fold higher in rabbit serum than in rat serum. The dose of paraoxon required to produce similar signs of toxicity and similar degrees of cholinesterase inhibition in rats and rabbits (0.5 and 2.0 mg/kg, respectively) differed by 4-fold. Paraoxonase was then purified from rabbit serum and 8.35 units was injected in the tail veins of rats, increasing the peak hydrolytic activity of rat serum by 9-fold toward paraoxon and by 50-fold toward chlorpyrifos-oxon. The increase in serum paraoxonase/chlorpyrifos-oxonase activity was long-lasting, with a 2- and 10-fold increase, respectively, still present after 24 hr. Thirty minutes following enzyme injection, rats were challenged with an acute dose of paraoxon or chlorpyrifos-oxon given by the intravenous, intraperitoneal, dermal, or oral route. Cholinesterase activities were measured in plasma, red blood cells, brain, and diaphragm after 4 hr. Rats pretreated with paraoxonase exhibited less inhibition of cholinesterase than vehicle-treated controls following identical doses of paraoxon, particularly when the organophosphate was given iv or dermally. A very high degree of protection, particularly toward brain and diaphragm cholinesterase, was provided by paraoxonase pretreatment in animals challenged with chlorpyrifos-oxon by all routes. These results indicate that levels of serum paraoxonase activity can affect the toxicity of paraoxon and chlorpyrifos-oxon.
...
PMID:Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. 169 Apr 62

Previous study in this laboratory showed that following a sc injection of an organophosphorus compound, diisopropyl fluorophosphate (DFP), into rats the inhibition of 10S molecular forms was considerably more pronounced than that of 4S forms of brain acetylcholinesterase (AChE). This could depend on different accessibility of the two forms or on their different intrinsic sensitivity to the antiChE compound. In the present study the effects of DFP and Paraoxon on 10S and 4S forms were evaluated in vivo, i.e., after systemic administration, and in vitro by adding the organophosphorus compounds to each of the two forms after extraction from brain of untreated rats, solubilization and separation. The in vivo preferential inhibition of 10S forms was confirmed. The 10S/4S ratios for control and DFP-treated rats were 9.05 and 5.01, respectively; these ratios were 8.46 and 3.33 for Paraoxon. On the other hand, in the in vitro experiments there were no significant differences between IC50 values for 10S and 4S forms both in the case of DFP (2.66 and 2.98 microM) and Paraoxon (32.4 and 42.4 nM, respectively). The overall data suggest that the preferential in vivo inhibition of 10S molecular forms with respect to 4S forms depends on their different accessibility probably due to different subcellular localization of the two forms and not on their different intrinsic sensitivity.
...
PMID:In vivo and in vitro effects of diisopropyl fluorophosphate and paraoxon on individual molecular forms of rat brain acetylcholinesterase. 207 31

The objective of this investigation was to distinguish which of the catalytic features of enzyme action is principally responsible for conferring the observed insensitivity of trout brain acetylcholinesterase (AChE; EC 3.1.1.7) to in vitro inhibition by organophosphates. The experimental design consisted of comparing the kinetic constants for the hydrolysis of a series of acylthiocholine substrates as well as the inhibition constants for a homologous series of dialkyl p-nitrophenyl phosphates among AChE from rats, hens, and trout. Chicken and rat brain AChE failed to distinguish between acetyl- and propionylthiocholine as inferred from the comparable Michaelis-Menten constants (Km), whereas trout brain AChE exhibited a much higher affinity for acetylthiocholine than for either of the two larger analogs. Diethyl p-nitrophenyl phosphate was the most potent inhibitor toward chicken and rat brain AChE, whereas the IC50 for the trout enzyme increased progressively between dimethyl and di-n-propyl p-nitrophenyl phosphate. The kinetic constants revealed that a significant determinant of inhibitor potency in the chicken and rat is steric exclusion as reflected by changes in the dissociation constant (Kd) which paralleled the changes in IC50 and ki. Conversely, Kd was 120- to 1450-fold higher and did not vary significantly for trout brain AChE. Instead, the phosphorylation rate constant (kp) for trout brain AChE decreased with progressive methylene substitutions. The kinetic data suggest that trout brain AChE not only possesses less steric tolerance, but also has a weaker nucleophile at the esteratic subsite, both of which may be important factors in conferring the observed insensitivity of trout to acute organophosphate intoxication.
...
PMID:Molecular determinants of the species-selective inhibition of brain acetylcholinesterase. 236 76

Homogenates of calf caudate nuclei were found to contain at least three distinct subclasses of cholinergic, muscarinic receptors. These subtypes, labeled with [3H]quinuclidinyl benzilate (QNB), can be separated by rapid filtration with the use of the selective ligands, pirenzepine, AF-DX116, and 4-DAMP which have high affinity for the M1, M2, and M3 subtypes, respectively. Paraoxon was found to modulate [3H]QNB binding in a noncompetitive manner at concentrations below those needed to affect acetylcholinesterase activity. Pretreatment of the membrane protein with high concentrations of both the M2 selective antagonist, AF-DX116, and the M3 selective antagonist, 4-DAMP, protected against paraoxon inhibition of [3H]QNB binding, while the M1 selective antagonist pirenzepine did not. Paraoxon sensitive sites, M2 and M3, are found predominantly on presynaptic neurons in the central nervous system. It is postulated that blockade of these sites may interfere with negative feedback inhibition of acetylcholine release and facilitate the development of behavioral and motor deficits that may be associated with chronic exposure to low levels of organophosphates.
...
PMID:Modulation of central muscarinic receptor binding in vitro by ultralow levels of the organophosphate paraoxon. 279 12

Paraoxon, 0,0-diethyl-0-p-nitrophenylphosphate is the highly toxic metabolite of parathion. The activity of paraoxonase, the enzyme which hydrolyses paraoxon in human serum shows a genetically influenced polymorphism with strong interethnic differences. The serum paraoxonase genotype has a significant influence on the paraoxon clearance and consequently on the toxic action of paraoxon and some related organophosphates and definitively protects the serum cholinesterase. Persons with low paraoxonase activity seem to be more endangered when handling parathion and related insecticides. More than 50% of all Europeans can be included in this group. The distribution of paraoxonase activity in human serum will be shown for samples which were collected from all over the world. As one moves from Europe in the direction of Africa and Asia the percentage of the low activity group decreases and was not even demonstrable in some tribes.
...
PMID:Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. 302 23

Rats treated intravenously with an organophosphorus anticholinesterase compound, paraoxon or soman, were sacrificed 2 to 131 min later, using 0.7 sec of focused microwave irradiation (25 kW at 915 MHz). Brain regional rates of glucose utilization during 3-min intervals were determined with labeled glucose and fluorodeoxyglucose as tracers. Levels of glucose, lactate, ATP, and creatine phosphate were assayed in the same samples. The two compounds differed markedly in their effects on brain metabolism. Paraoxon (0.8 LD50) depressed rates of glucose use in all brain regions, without causing consistent changes in brain metabolite levels. This depressant effect was most pronounced during the first 30 min after toxin exposure and had largely disappeared by 2 hr. Soman (0.8-0.95 LD50) was variable in its effects. Animals that showed seizure-like behavior had marked increases in glucose use in diencephalon and cerebrum but no changes in cerebellum or brain stem. Rapid rates of glucose use were associated with high levels of lactic acid and lower levels of creatine phosphate. In cerebrum, but not diencephalon, levels of ATP fell by as much as 50% in strongly affected animals by 30-130 min after soman. All of these effects were reversible with atropine. Soman-treated animals that did not have seizure-like activity did not exhibit these brain metabolic changes. These results and those of others show that cholinergic compounds vary greatly in their effects on brain glucose and energy metabolism. Although noncholinergic mechanisms are a possibility, the most parsimonious explanation for these findings is that cholinesterase inhibitors vary in their affinity for different central nervous system (CNS) acetylcholine receptor populations.
...
PMID:Cerebral metabolic effects of organophosphorus anticholinesterase compounds. 350 39


1 2 3 4 5 6 7 Next >>

---